Phys.OrgActive genetics technology opens new horizonsPhys.Org"Technical advances enabled by active genetics represent an innovative toolkit to engineer organisms with novel features, thereby enabling a new era of advances in synthetic biology,&quo… Continue reading
HPCwire (blog)IARPA Ramps Up Molecular Information Storage ProgramHPCwire (blog)Multiple, diverse approaches are anticipated, which may utilize DNA, polypeptides, synthetic polymers, or other sequence-controlled polymer media. TA2 (Retrieval).Develop a… Continue reading
EurekAlert (press release)Scientists make it possible to rank the risk of resistance genesEurekAlert (press release)The researchers exploited synthetic biology to sample a large mechanistic diversity of resistance genes to investigate the impact of gen… Continue reading
Curetoday.com |
Body Mass Index Plays a Surprising Role in Immunotherapy’s Effectiveness
Curetoday.com “Obesity has been previously investigated for its role in cancer and promoting tumor growth, at least partially by inducing a chronic inflammatory state,” the authors wrote. “However, it’s unclear how this would play out in the era of immunotherapy … |
Curetoday.com |
Body Mass Index Plays a Surprising Role in Immunotherapy’s Effectiveness
Curetoday.com “Obesity has been previously investigated for its role in cancer and promoting tumor growth, at least partially by inducing a chronic inflammatory state,” the authors wrote. “However, it’s unclear how this would play out in the era of immunotherapy … |
|
Roche notches fresh win amid crowd of immunotherapy cocktails
Reuters ZURICH, Feb 6 (Reuters) – Roche’s Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker’s immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals … |
|
Roche notches fresh win amid crowd of immunotherapy cocktails
Reuters ZURICH, Feb 6 (Reuters) – Roche’s Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker’s immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals … |